Abstract: The present invention provides a device and a system for the delivery of biological material across the biological tissue. The device may be for the programmed delivery of biological material through a needle or a micro-needle or micro-needles or biodegradable micro-needles.

Abstract: An improved method for treatment of malignancies is based on the interaction between nerve cells and angiogenesis of malignancies. In general, the method comprises: (1) harvesting neural stem cells; (2) culturing neural stem cells under conditions such that the cells proliferate while retaining their ability to differentiate; (3) applying a biocompatible adhesive to a post-surgical site of a malignancy; and (4) following the application of the biocompatible adhesive to the post-surgical site of the malignancy, applying the cultured neural stem cells to the post-surgical site of the malignancy to remove residual tumor cells and to induce endothelial cell apoptosis. The method can further comprise the administration of a therapeutically effective quantity of at least one anti-neoplastic therapeutic agent or administration of a therapeutically effective quantity of anti-neoplastic ionizing radiation. The invention further encompasses kits for use in treating malignancies.

Abstract: A system for moving particles suspended in a first fluid, and for infusing them into the stream of a second fluid, includes a catheter with a multi-lumen distal tip. The tip is formed with a plurality of parallel lumens, wherein each lumen has a predetermined diameter. Importantly, the diameter of each lumen is dimensioned to sequentially receive particles therethrough, to prevent the particles from flocculating before they enter the stream of the second fluid. A valve, affixed to the outside of the catheter, can be provided to regulate flow of the second fluid and thereby facilitate entry of the particles into the stream of the second fluid.

Abstract: Described herein generally are catheter systems used to deliver cells and other bioactive materials to a target location within the vascular system of the human body, and methods of delivering cells and other bioactive materials to such target locations.

Abstract: The present invention is directed to systems and methods for delivering therapy for a cardiac disorder, wherein the system comprises a source for supplying a protein formulation containing a protein that is otherwise deficient in cardiac cells in a patient with a cardiac disorder, and a catheter having a proximal end and a distal end for delivering the protein formulation to the pericardial sac region of a human heart.

Abstract: A minimally invasive fat cell removal system and method is provided using a numbing component, a laser component, and a NIL component. A cannula and fiber of the laser component are insertable into a body of a patient at a biopsy punch to liquefy a fat cell via a tumescent fluid and/or a laser. A NIL cannula of the NIL component is insertable into the body to remove the fat cell via suction and/or nutation. An anesthetic device of the numbing component may reduce sensation of the body where the cannula is insertable. The fat cell may be harvested and implanted at another location of the body.

Abstract: A bone fastener or an orthopedic implant that resides within the bone after orthopedic surgery has a threaded and/or unthreaded shaft, said shaft has a hollow portion and a solid portion. The hollow portion may have a structure that enhances tissue growth and may also hold materials that enhance tissue growth. The hollow portion may also hold materials to treat diseases and/or promote bone fracture healing.

Abstract: Provided herein are devices and methods for anterior arytenoid adduction. The device may comprise a wire having a first end and a second end at opposite ends of a longitudinal axis, the wire forming a spiral along the longitudinal axis and having a double hook at the first end, a suture threaded through the spiral of the wire from the second end to the first end, the suture forming a turn at the first end and passing exterior to the spiral to the second end. The method may comprise advancing a suture and hook from the subject's anterior thyroid cartilage or cricothyroid membrane to the muscular process of the subject's arytenoid, attaching the hook to the muscular process, and applying tension to the suture to rotate the muscular process and adduct the arytenoid.

Abstract: A method and device are herein described to treat a target region of tissue, using at least one energy delivery device coupled to a power source and positioned in a treatment position so as to irreversibly electroporate tissue to ablate a target region, and introduce regenerative materials into a treated region.

Abstract: The invention provides an isolated or purified nucleic acid comprising a nucleotide sequence encoding a nuclear factor of activated T-cells (NFAT) promoter operatively associated with a nucleotide sequence encoding IL-12. The invention also provides a nucleic acid comprising a nucleotide sequence encoding a nuclear factor of activated T-cells (NFAT) promoter operatively associated with a nucleotide sequence encoding IL-12, wherein the NFAT promoter is located 3? of the nucleotide sequence encoding IL-12. Also provided are related recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. The invention further provides the use of the inventive nucleic acids or related materials in the treatment or prevention of cancer or an infectious disease in a mammal and in the induction of IL-12 expression in a mammal.

Abstract: Endoluminally delivered tissue patches and related systems and methods for delivering the tissue patches for treating lesions of the alimentary tract are disclosed. A system for delivering a tissue implant includes a catheter having an expandable member at a distal end portion, a carrier placed around the expandable member, and the carrier configured to expand from a contracted state to an expanded state and to receive the tissue implant. The tissue implant contacts the lesion of the alimentary tract when the expandable member expands the carrier to the expandable state.

Abstract: A medical practitioner can specify certain parameters for a procedure that involves delivering a therapeutic agent, while leaving other parameters open. The therapeutic agent can be sensitive to biomechanical forces (or other influences) associated with delivery. The procedure can involve regenerative medicine, for example delivering progenitor or stem cells to a diseased heart using a catheter, whereby unbridled transport in the catheter may compromise efficacy. The open parameters can influence efficacy of the agent and thus therapeutic outcome. A computer-based system can apply stored information, such as from databases, to narrow the possible values of the open parameters. From the narrowed possibilities, an optimization routine can determine suitable or optimized values for the open parameters. The determined values can manage biomechanical forces incurred by the therapeutic agent, thereby promoting efficacy and healing. The optimized parameters can guide the practitioner in the procedure.

Abstract: This invention provides novel carbonic anhydrase (CAIX) nucleic acid and peptide sequences, as well as related methods and compositions, including anti-cancer immunogenic agent(s) (e.g. vaccines and chimeric molecules) that elicit an immune response specifically directed against cancer cells expressing a CAIX antigenic marker. The novel CAIX variant and related compositions are useful in a wide variety of treatment modalities including, but not limited to protein vaccination, DNA vaccination, adoptive immunotherapy.

Abstract: Centrifuges are useful to, among other things, remove red blood cells from whole blood and retain platelets and other factors in a reduced volume of plasma. Platelet rich plasma (PRP) can be obtained rapidly and is ready for immediate injection into the host. Embodiments may include valves, operated manually or automatically, to open ports that discharge the excess red blood cells and the excess plasma while retaining the platelets and other factors. High speeds used allow simple and small embodiments to be used at the patient's side during surgical procedures. The embodiments can also be used for the separation of liquids or slurries in other fields such as, for example, the separation of pigments or lubricants.

Abstract: A closure device having evertable arms for capturing and everting tissue and method for its use with an invasive scope, such as an endoscope, for full-thickness closure of perforations and leaks in the walls of an intraluminal bodily space.

Abstract: There is provided a G protein coupled receptor (GPCR) or a polynucleotide encoding said GPCR for use as a vaccine. There is also provided methods of antagonising or agonising A GPCR in vivo comprising the administration of a GPCR or a polynucleotide encoding a GPCR to a subject. The invention further provides a GPCR for use in inhibiting an activity of a GPCR binding partner in a subject.

Abstract: An apparatus that allows for separating and collecting a fraction of a sample. The apparatus, when used with a centrifuge, allows for the creation of at least three fractions in the apparatus. It also provides for a new method of extracting the buffy coat phase from a whole blood sample. A buoy system that may include a first buoy portion and a second buoy member operably interconnected may be used to form at least three fractions from a sample during a substantially single centrifugation process. Therefore, the separation of various fractions may be substantially quick and efficient.

Abstract: Method of preparing a clogged animal vessel, e.g. chronic total occlusion of an artery so as to be capable of crossing by a guidewire of an intraluminal device, e.g., angioplasty balloon. The method includes delivering an angiogenic agent to the occlusion site to promote angiogenesis within the occlusion to increases susceptibility to crossing.

Abstract: Disclosed are viral vector compositions comprising polynucleotide sequences that express one or more biologically-active mammalian guanylate cyclase proteins. Also disclosed are methods for their use in preventing, treating, and/or ameliorating at least one or more symptoms of a disease, disorder, abnormal condition, or dysfunction resulting at least in part from a guanylate cyclase deficiency in vivo. In particular embodiments, the use of recombinant adeno-associated viral (rAAV) vectors to treat or ameliorate symptoms of Leber's congenital amaurosis, as well as other conditions caused by an absence or reduction in the expression of a functional retinal-specific guanylate cyclase 1 (retGC1).

Abstract: Provided herein is a method of delivering nucleic acid molecules to a compartmentalized tissue or organ of a subject. Also provided herein are uses and processes for delivering a nucleic acid molecule to the parenchyma of a compartmentalized tissue or organ. The methods and uses can be used in the treatment of diseases and conditions and in industrial, agricultural and veterinary applications. Also provided herein are compositions containing an adenovirus or adeno-associated virus or other recombinant virus formulated for administration to the parenchyma of a tissue or organ.

Abstract: Described herein are methods for delivering live cells into tissue, such as skin or other animal tissue, that has been treated with a laser (e.g. at a minimally coagulating setting) to produce voids/channels/grooves in the tissue. It has been surprisingly discovered that voids having a minimal coagulation zone around the ablation void provide a receptive environment into which live cells are readily delivered (without the need for injections into the target tissue) and can therefore survive and persist.

Abstract: Methods and compositions for differentiating tissue resident multipotent mesenchmal stromal cells (MSCs) such as adipose tissue resident MSCs into a hematopoietic lineage are described.

Abstract: The present invention relates to methods to prepare red blood cells (RBCs) for infusion to a patient. Depletion of RBCs with altered deformability is achieved by filtration through micro-bead filters.

Abstract: The invention relates to compositions, methods, and kits for treating subjects infected by or at risk of infection with a DNA virus (e.g., a JC Virus or a BK virus). Aspects of the invention are useful to prevent or treat DNA virus associated conditions (e.g., PML) in subjects that are immunocompromised. Compositions are provided that inhibit intracellular replication of DNA viruses.

Abstract: Extracorporeal systems and methods for treating blood-borne diseases in a subject or for developing drugs to treat blood-borne diseases include various environmental and treatment modules that can be tailored to a specific disease or infection. In certain embodiments of the systems and methods, a blood sample is treated with cold plasma and optionally with hydrostatic pressure, a pulsed electrical field, a pharmaceutical agent, microwave, centrifugation, sonification, radiation, or a combination thereof, under environmental conditions that are effective for the treatment.

Abstract: The present invention provides for the identification of autoreactive T cell populations from individuals having autoimmune diseases, such as multiple sclerosis and EAE. Peptoids recognized by autoreactive T cells can be used to identify various types of autoimmune disease, and can also be used to target therapies against such populations.

Abstract: The present invention relates to oncolytic Picornaviruses and methods and compositions for treating subjects having hematologic cancers. These include methods and compositions for treatment of myeloma, using disclosed Picornavirus such as Coxsackievirus, in methods of direct or indirect administration to subjects and ex vivo purging of malignant cells within auto grafts prior to transplantation.

Abstract: Methods of treating heart failure by administration of beneficial agents to the heart.

Abstract: The invention provides methods for reducing diabetes susceptibility in a subject and methods for increasing the expression of LL or CLORF32 in a subject. The invention further provides a method for identifying an agent which modulates expression of an Ll RNA or Clorf32 RNA comprising contacting a cell with an agent; determining expression of the Ll RNA or Clorf32 RNA in the presence and the absence of the agent; and comparing expression of the Ll RNA or Clorf32 RNA in the presence and the absence of the agent, wherein a change in the expression of the Ll RNA or Clorf32 RNA in the presence of the agent is indicative of an agent which modulates the level of expression of the RNA.

Abstract: The present invention relates to systems and apparatuses for improving quality and viability of biological material, such as harvested adipose cells, stem cells, or other cells or biological components, by treatment of the biological material with membrane-repairing/stabilizing agents or the like and/or mechanical removal of components, such as impurities and/or excess treatment agents. The present invention further relates to systems and apparatuses for transplanting tissue, such as adipose tissue.

Abstract: A device and method for oxygenating blood is disclosed herein. The device includes a plurality of passive mixing elements that causes a fluid to mix as it flows through the device. The passive mixing elements continually expose new red blood cells to the portion of the flow channel where oxygenation can occur. Accordingly, in some implementations, the device and method uses less blood to prime the device and allows for the oxygenation of blood with a substantial shorter flow channel when compared to conventional oxygenation methods and devices.

Abstract: The current invention discloses methods to treat disease caused by virus infection, bacterial infection, parasites infection, autoimmune disease, disease caused by production of unwanted antibodies, sepsis as well as methods to treat cancer and methods for virus infection detection using blood purification method. The current invention provides a method to treat pathogen infection by inactivating the pathogens in the blood. During the treatment, blood is withdrawn from a patient and is separated into its plasma and cellular components. The plasma portion is treated with physical means such as UV radiation to inactivate the pathogens inside and then is returned to the patient. The current invention also provide a method to treat cancer especially to prevent tumor metastasis and tumor recurrence by removing and/or inactivating (e.g. killing) the circulating tumor cells (CTC) in the blood after removing the tumor or treating the tumor with therapeutical means.

Abstract: Methods and compositions for the prevention or reduction of platelet transfusion associated complications are provided. Methods are provided to modify donor whole blood or platelets prior to transfusion to prevent or reduce alloimmune platelet refractoriness.

Abstract: An efficient and simplified method for preparing and sorting fused cells is described herein. This approach yields fused cells useful in a variety of applications, including clinical treatment regimens, as cellular modulators of the immune system.

Abstract: A biologic ventricular assist device that also has the capability to capture, grow, and administer stem cells to regenerate and restore damaged myocardium in the heart. The device works in conjunction with a traditional ventricular assist device and possesses an additional external path or tube that is in-line with the path of the ventricular assist device. The external path allows for the administration of stem cells, genes, genetically modified cells or other therapeutic biologic or pharmacologic agents, as well as leading to a stem cell collecting accessory that captures circulating stem cells. The stem cell collecting accessory is also associated with a chamber for culturing the captured stem cells.

Abstract: A filter apparatus for removing small molecule chemotherapy agents from blood is provided. The filter apparatus comprises a housing with an extraction media comprised of polymer coated carbon cores. Also provided are methods of treating a subject with cancer of an organ or region comprising administering a chemotherapeutic agent to the organ or region, collecting blood laded with chemotherapeutic agent from the isolated organ, filtering the blood laden with chemotherapeutic agent to reduce the chemotherapeutic agent in the blood and returning the blood to the subject.

Abstract: Disclosed herein are methods and devices for processing a biomaterial in a closed system and administering the processed biomaterial to a subject.

Abstract: The present inventions are directed to compositions and methods regarding the reprogramming of other cells (such as fibroblast cells) into cardiomyocytes without introducing exogenous genes to the samples. In particular, the present inventions are directed to transducible materials that are capable of transducing into the biological samples but are not genes or causing genetic modifications. The present inventions also are directed to methods of reprogramming the path of biological samples or treating diseases using the tranducible compositions thereof.

Abstract: The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The cargo compound may be a nucleic acid and specifically a DNA, RNA or anti-sense. The invention further discloses methods for treating cancer and diagnosing cancer.

Abstract: In accordance with certain embodiments of the present disclosure, a kit is described. The kit includes primed living cells joined to and at least partially within a three-dimensional hydrogel structure and an isolated polypeptide having the carboxy-terminal amino acid sequence of an alpha Connexin, or a conservative variant thereof, wherein the polypeptide does not include the full length alpha Connexin protein.

Abstract: An improved method for preparing an adipose tissue biocomposite graft to serve a wide range of medical applications is presented. In particular, the embodiments consider a performing lipoplasty to derive a plurality of adipose tissue fragments containing at least one viable stem cell from a donor, harvesting said plurality of adipose tissue fragments from said donor, placing said plurality of adipose tissue fragments in contact with appropriate concentrations of a thrombin source and a fibrinogen source to achieve an appropriate gelling reaction and applying the mixture of said adipose tissue fragments, said thrombin source and said fibrinogen source to a wound site of the donor so as to promote wound healing. The adipose biocomposite graft of the present invention can be easily processed, molded and customized to precise dimensions. The present invention employs a three dimensional mold cavity to prepare multiple castings of said adipose tissue biocomposite grafts for an individual donor.

Abstract: To control cardiac arrhythmias such as atrial fibrillation post-operatively, various non-ablative agents include polymers, fibroblasts, neurotoxins, and growth factors are introduced into one or more cardiac fat pads into the atrioventricular nodal fat pad in proximity to the autonomic ganglia therein. Any desired technique may be used for introducing the agent, including injection. The sinoatrial nodal fat pad target site and the atrioventricular nodal fat pad target site are identified using a stimulator, which may have electrodes coupled thereto or which may coupled to electrodes built into a delivery system.

Abstract: The present disclosure provides methods for treating multiple myeloma using autologous expanded and activated NK cells.

Abstract: Methods of inhibiting metastasis in cancer patients are provided, wherein the methods comprise reducing TGF? signaling, for example, by reducing TGF receptor II expression in myeloid cells. Vectors comprising a TGF? receptor II RNAi nucleic acid sequence operably linked to a myeloid specific promoter also are provided. A method of diagnosing cancer in an individual by determining TGF? receptor II expression in myeloid cells in the individual is provided. Additionally, a method of modulating TGF? activity in myeloid cells in a cancer patient comprising administering a regulator of at least one of the GSK3 and PI3K pathways to the patient is provided.

Abstract: Methods and apparatus are provided for delivering a bioactive agent in a needle track formed in a target tissue mass, following formation of the needle track, by avoiding impingement of the agent against target tissue at high velocity or by using capillary action to draw the bioactive agent out of the needle during needle withdrawal. The apparatus comprises a catheter and a needle disposed within the catheter and configured to be selectively extended into the tissue mass to a predetermined depth, while dispensing the agent simultaneously with retraction of the needle along the needle track. Alternatively, or in addition, the needle may be configured to create a tissue space surrounding a distal or lateral surface of the needle, into which the bioactive agent to be infused.

Abstract: The present invention relates to a pharmaceutical composition comprising glucocorticoid (GC)-induced human monocytes, and optionally a pharmaceutically acceptable carrier.

Abstract: Disclosed herein are methods for inducing an immunological CTL response to an antigen by sustained, regular delivery of the antigen to a mammal so that the antigen reaches the lymphatic system. Antigen is delivered at a level sufficient to induce an immunologic CTL response in a mammal and the level of the antigen in the mammal's lymphatic system is maintained over time sufficient to maintain the immunologic CTL response. Also disclosed is an article of manufacture for delivering an antigen that induces a CTL response in an animal.

Abstract: A method for delivering a therapeutic substance to a treatment site within a body lumen includes advancing a balloon catheter to the treatment site. A balloon of the balloon catheter is inflated and while the balloon is inflated, a primer that coats the treatment site and attracts the therapeutic substance thereto is delivered through a first fluid delivery lumen of the balloon catheter. The balloon of the balloon catheter is deflated for a predetermined period of time. The balloon of the balloon catheter is reinflated and while the balloon is reinflated, the therapeutic substance is delivered through a second fluid delivery lumen of the balloon catheter. The primer improves adherence of the therapeutic substance to the treatment site.

Abstract: The present invention provides for methods and materials for detecting a peripherin-specific autoantibody, which can be associated with neurological and endocrinological disease.

Abstract: This invention relates to a method and an apparatus of controlling a release of a material carried by ultrasound sensitive particles, the release being caused by irradiating the ultrasound sensitive particles with an ultrasonic pulse having acoustic properties selected so as to interact with the ultrasound sensitive particles and thus causing the release of the material. The ultrasound sensitive particles comprise sub-groups of ultrasound sensitive particles, the ultrasound sensitive particles within the same sub-group having their respective acoustic property causing each respective sub-group to interact independently with the sound wave.